Table 4 Cumulative resistance rates with continuous 4-year telbivudine treatment in HBeAg-positive and HBeAg-negative Taiwanese patients showing an HBV DNA decline of >5 log 10 copies/mL and ≤5 log 10 copies/mL
HBeAg-positive patients (%) | HBeAg-negative patients (%) | ||
|---|---|---|---|
Genotypic resistance to telbivudine | Year 4 | 43.8% | 12.5% |
Predictive factors at Week 24 | |||
Undetectable/Detectable levels of HBV DNA | Year 4 | 0%/77.8% | 8.7%/100% |
Achieved/Non-achieved reduction of 5 log10 copies/mL | Year 1 | 0%/0% | NA |
Year 2 | 7.6%/75% | NA | |
Year 3 | 15%/100% | NA | |
Year 4 | 15%/100% | NA |